Skip to main content
data science

081: Data Science Will Accelerate Your Research – with Joel Schwartz, PhD

As a graduate student, Joel Schwartz developed an immunofluorescence assay for neurotransmitter transport. To quantify his results, he needed to circle the cells in each image so the computer could measure the intensity.

By the time he graduated, Joel had circled over 10 million individual cells.

Over the years, Joel discovered a better way: he taught computers to do the repetitive, complex, and confounding parts of data analysis.

And now he trains other scientists to do the same.

(more…)

blood test

053: Why more testing from Theranos won’t prevent cancer

It’s a compelling promise: take a few drops of blood, and tell the patient what hidden diseases are lurking in his body.  If only we could have an early warning system for cancer, Alzheimer’s, or myriad other diseases, then we could treat them before they took hold.

This is the narrative of Theranos, a company that wants to make medical testing affordable and fast for everyone.  They’ve taken the notion so far that they actually publish a price list for hundreds of tests right on their website.theranos price list

Recently, the company made less favorable headlines when the Wall Street Journal revealed that many of the tests were performed on industry standard equipment, rather than the space-age technology Theranos markets.

The company’s troubles deepened when federal regulators announced plans to revoke the license of one of its lab facilities and to ban CEO and founder Elizabeth Holmes from the industry for two years.

But technology and regulations aside, there’s a more fundamental question we should all be asking: is wider access to routine screening a good thing?

The math says no.

(more…)